Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02319044
Title Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

head and neck squamous cell carcinoma

Therapies

Durvalumab

Tremelimumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.